학술논문
SWITCH TO DOR/ISL (100/0.75MG) QD FROM B/F/TAF: WEEK 48 RESULTS FROM A PHASE 3 TRIAL.
Document Type
Article
Author
Source
Topics in Antiviral Medicine; Apr2023, Vol. 31 Issue 2, p81-81, 1/2p
Subject
Language
ISSN
21615861